Dr Neil Mehta discusses the recent updates on policies for liver transplantation in patients with hepatocellular carcinoma (HCC).
Dr Neil Mehta discusses the recent updates on policies for liver transplantation in patients with hepatocellular carcinoma (HCC).
Dr Neil Mehta underwent medical training at the University of California, San Francisco (UCSF). He was an Intern then a Resident at the Hospital of the University of Pennsylvania before becoming a Fellow in Gastroenterology and Transplant Hepatology at UCSF. He is Associate Professor in Medicine at UCSF and has held this position since 2013. He is specifically interested in issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.
Fujifilm Wako
Survey findings presented at ONS 2025 and published in the journal Healthcare
What to know, what to expect, and where to find support
Optimising 1st and 2nd line treatment
Optimising precision medicine for improved patient outcomes
A closer look at the evolving treatment landscape
Experts' insights on treatment strategies in ER+ metastatic breast cancer settings